Literature DB >> 16042357

Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays.

A Vermeulen1.   

Abstract

While the typical symptomatology of severe hypogonadism in young adults permits the clinical diagnosis of hypoandrogenism, the diagnosis of partial androgen deficiency of the aging male (PADAM), as occurs relatively frequently in elderly males, is much more difficult. This is due to its clinical picture being subtle and aspecific, and to the fact that both clinical and biochemical evidence of androgen deficiency are required for the diagnosis. In the absence of a practical, clinical useful parameter of androgen activity, we have to rely upon bio-active plasma testosterone levels. Although the requirements of androgens in elderly males may be different from those in young, healthy adults, the lower limit of levels observed in the latter is generally used to define biochemical hypoandrogenism. Based on these data, we consider 11 nmol/l of testosterone, 0.225 nmol/l of free testosterone (FT) and 5.3 nmol/l of biotestosterone (bio-T) as the lower normal limits. As even when using the same kits, values for plasma testosterone and SHBG may differ significantly between laboratories, each laboratory should define its own normal values. As to the methodology, neither direct measurement of free testosterone by analog assay, nor the FT index (T/ SHB) can be recommended, only values obtained by dialysis, ammoniumsulfate precipitation or calculation yielding reliable estimates of androgen bio-activity. Dialysis and ammoniumsulfate precipitation are however work intensive and not widely used.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042357

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  10 in total

Review 1.  Importance of hypogonadism and testosterone replacement therapy in current urologic practice: a review.

Authors:  Wayne J G Hellstrom; Darius Paduch; Craig F Donatucci
Journal:  Int Urol Nephrol       Date:  2010-12-09       Impact factor: 2.370

Review 2.  Diagnosis and treatment of infertility-related male hormonal dysfunction.

Authors:  Martin Kathrins; Craig Niederberger
Journal:  Nat Rev Urol       Date:  2016-04-19       Impact factor: 14.432

3.  Comparing calculated free testosterone with total testosterone for screening and diagnosing late-onset hypogonadism in aged males: A cross-sectional study.

Authors:  Zhangshun Liu; Jie Liu; Xiaohong Shi; Lihong Wang; Yan Yang; Minfang Tao; Qiang Fu
Journal:  J Clin Lab Anal       Date:  2016-10-07       Impact factor: 2.352

4.  Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women.

Authors:  L-A Fraser; D Morrison; P Morley-Forster; T L Paul; S Tokmakejian; R Larry Nicholson; Y Bureau; T C Friedman; S H M Van Uum
Journal:  Exp Clin Endocrinol Diabetes       Date:  2008-06-03       Impact factor: 2.949

5.  Serum testosterone level and related metabolic factors in men over 70 years old.

Authors:  Y-J Tang; W-J Lee; Y-T Chen; P-H Liu; M-C Lee; W H H Sheu
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

Review 6.  [The "obese" and "old" male patient in dermatological practice. When should hypogonadism be considered?].

Authors:  D Varwig-Janßen; F Ochsendorf
Journal:  Hautarzt       Date:  2015-12       Impact factor: 0.751

7.  Partial androgen deficiency, depression, and testosterone supplementation in aging men.

Authors:  Mario Amore; Marco Innamorati; Sara Costi; Leo Sher; Paolo Girardi; Maurizio Pompili
Journal:  Int J Endocrinol       Date:  2012-06-07       Impact factor: 3.257

8.  Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.

Authors:  Bruno Lunenfeld; George Mskhalaya; Michael Zitzmann; Stefan Arver; Svetlana Kalinchenko; Yuliya Tishova; Abraham Morgentaler
Journal:  Aging Male       Date:  2015-02-06       Impact factor: 5.892

9.  The benefits and risks of testosterone replacement therapy: a review.

Authors:  Nazem Bassil; Saad Alkaade; John E Morley
Journal:  Ther Clin Risk Manag       Date:  2009-06-22       Impact factor: 2.423

10.  Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations.

Authors:  C Wang; E Nieschlag; R Swerdloff; H M Behre; W J Hellstrom; L J Gooren; J M Kaufman; J-J Legros; B Lunenfeld; A Morales; J E Morley; C Schulman; I M Thompson; W Weidner; F C W Wu
Journal:  Eur J Endocrinol       Date:  2008-11       Impact factor: 6.664

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.